Compare HAIN & MREO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HAIN | MREO |
|---|---|---|
| Founded | 1993 | 2015 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Packaged Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 53.7M | 50.3M |
| IPO Year | 1996 | 2017 |
| Metric | HAIN | MREO |
|---|---|---|
| Price | $0.49 | $0.35 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 9 | 5 |
| Target Price | ★ $2.23 | $1.50 |
| AVG Volume (30 Days) | 1.5M | ★ 1.6M |
| Earning Date | 05-11-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 42.95 | 16.67 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,457,769,000.00 | $500,000.00 |
| Revenue This Year | N/A | $5,184.20 |
| Revenue Next Year | N/A | $55.51 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.48 | $0.20 |
| 52 Week High | $1.69 | $2.37 |
| Indicator | HAIN | MREO |
|---|---|---|
| Relative Strength Index (RSI) | 34.18 | 66.87 |
| Support Level | N/A | $0.31 |
| Resistance Level | $0.64 | $0.35 |
| Average True Range (ATR) | 0.06 | 0.02 |
| MACD | -0.02 | 0.01 |
| Stochastic Oscillator | 4.03 | 82.55 |
The Hain Celestial Group Inc is a health and wellness company. It makes natural and organic food and personal-care products. The company offers products across various categories such as snacks, baby & kids food, beverages, meal preparation, and personal care through brands like Garden Veggie Snacks, Terra chips, Garden of Eatin snacks, Hartley's Jelly, and Celestial Seasonings teas, among others. It operates under two reportable segments: North America and International. The majority of its revenue is derived from the North America segment, which represents the sale of its products in the United States and Canada. The International segment includes the sale of its products in the United Kingdom and the Western European region.
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat, mainly for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).